Is protracted low-dose temozolomide feasible in glioma patients?
The authors investigated the safety of 75 mg/m2 temozolomide for 21 days every 28 days in glioma patients. This schedule could lead to DNA repair enzyme O6-alkylguanine-DNA alkyltransferase depletion, contributing to overcoming drug resistance. Although Phase III studies are forthcoming, no data are available on the long-term toxicity of temozolomide, which, in this series, incurred prolonged, cumulative lymphopenia, which leads to a high incidence of infections.
Tosoni
A
A
Department of Medical Oncology, University Hospital of Padova, Padova, Italy.
Cavallo
G
G
Ermani
M
M
Scopece
L
L
Franceschi
E
E
Ghimenton
C
C
Gardiman
M
M
Pasetto
L
L
Blatt
V
V
Brandes
A A
AA
D000328:Adult; D000368:Aged; D018906:Antineoplastic Agents, Alkylating / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D016543:Central Nervous System Neoplasms / Q000188:drug therapy*; D003606:Dacarbazine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005240:Feasibility Studies; D005260:Female; D005910:Glioma / Q000188:drug therapy*; D006801:Humans; D007239:Infections / Q000209:etiology; D008231:Lymphopenia / Q000139:chemically induced* / Q000150:complications; D008297:Male; D008875:Middle Aged; D000077204:Temozolomide
D018906:Antineoplastic Agents, Alkylating; D003606:Dacarbazine; D000077204:Temozolomide